NCT06773377Not yet recruiting
Study of the Prognostic Impact of CD44 on Renal Cell Carcinoma
Source: ClinicalTrials.gov · Last updated 14 Jan 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
1. Study the expression of CD44 in various histopathological types of RCC. 2. Study the association between CD44 expression and other clinicopathological parameters 3. study the impact of CD44 expressions in tumor and patients' survival
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 77 (estimated)
- First submitted
- 9 Jan 2025
- Start date
- 1 Nov 2025
- Primary completion date
- 1 Nov 2026
- Lead sponsor
- Assiut University
- Diseases
- Kidney cancer
- NCT number
- NCT06773377
What you commit to
- Study type: Observational
- Planned participants: 77
- From 1 Nov 2025 to the primary completion date, 1 Nov 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- The presence of any other organ malignancies
Other
- Patients who lost follow-up after nephrectomy less than 3-year,
- Patients with incomplete pathological data
Who the study is looking for
- patient must be more than 18 years
- Patients with complete pathological data
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.